Unit:
Κατεύθυνση Βασική ΈρευναLibrary of the School of Health Sciences
Supervisors info:
Μιχαήλ Κουτσιλιέρης, Καθηγητής, Τμήμα Ιατρικής, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
Κλειώ Μαυραγάνη, Αναπληρώτρια Καθηγήτρια, Τμήμα Ιατρικής, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών, Επιβλέπουσα
Ελένη Κοτσιφάκη, Αναπληρώτρια Καθηγήτρια, Τμήμα Ιατρικής, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
Original Title:
O Ρόλος της Δραστικότητας της Lp-PLA2 Φωσφολιπάσης στη Λεμφωμαγένεση του Συνδρόμου Sjogren
Translated title:
The Role of Phospholipase Lp-PLA2 Activity in Sjogren's Syndrome Related Lymphomagenesis
Summary:
Background: One of the major complications of primary Sjogren's syndrome (SS) is the development of B-cell non-Hodgkin's lymphoma (B-NHL). The contribution of tissue macrophages in the pathogenesis of B-NHL, based on previous histopathological studies, is significant. Extracellular lipoprotein-associated phospholipase A2 (Lp-PLA2) is a product of tissue macrophages which is found in the circulation associated with lipoproteins and has been involved in both cardiovascular and malignant diseases, including B-NHL lymphoma.
Objective: The purpose of the current study was to investigate the role of serum Lp-PLA2 activity as a potential biomarker for the development of B-NHL in the setting of primary SS.
Methods: Lp-PLA2 activity in serum was determined by measuring [3H]PAF degradation products by liquid scintillation. The samples were obtained from 48 primary SS patients, 9 primary SS patients with lymphoma (SS-lymphoma) and 40 healthy controls. Additionally, an independent cohort of 25 primary SS patients, 17 primary SS-lymphoma and 10 healthy controls were tested using a commercially available ELISA kit. Lp-PLA2 mRNA and protein expression in minor salivary gland tissue samples derived from our cohort patients were also evaluated by Real-Time PCR and Western Blot, respectively.
Results: The activity of Lp-PLA2 showed statistically significant increase in patients with primary SS-lymphoma compared to primary SS patients without lymphoma [mean±SD (nmol/min/ml): 62.0±13.4 vs 47.7±14.7, p=0.003 and 19.7±4.7 vs 15.2±3.2, p=0.005, respectively], as well as healthy controls [mean±SD (nmol/min/ml): 62.0±13.4 vs 52.0±16.3, p=0.03 and 19.7±4.7 vs 15.7±3.1, p=0.06, respectively]. No statistically significant difference in Lp-PLA2 activity was observed between primary SS patients without lymphoma development and healthy controls. Lp-PLA2 mRNA and protein expression were found to be increased in SS patients with lymphoma, compared to SS without lymphoma and sicca controls (p<0.05).
Conclusions: Evaluation of extracellular Lp-PLA2 activity in primary SS patients may serve as a useful serological biomarker for B-NHL development in the context of primary SS.
Main subject category:
Health Sciences
Keywords:
Sjogren's syndrome, Lymphoma, Phosholipase activity, Lipoprotein lipase A2, Western Blot, Real time PCR, Immunohistochemistry
Number of references:
261
